29
Participants
Start Date
September 30, 2010
Primary Completion Date
July 31, 2012
Study Completion Date
February 28, 2013
ART Intensification
Current ART regimen plus raltegravir and maraviroc Raltegravir : 400 mg PO BID for 56 weeks Maraviroc : 150, 300 or 600 mg PO BID depending on concomitant ART treatment, for 56 weeks
Immunomodulation
Starting at Week 8, 1 cycle of 3 injections (1 per week) of recombinant human Interleukin-7 (r-hIL-7 / CYT107) at a 20 µg/kg dose.
San Raffaele Scientific Institute, Milan
Groupe Hospitalier Pitié-Salpêtrière, Paris
Fundacio Irsicaixa, Badalona
University Hospital Clinic of Barcelona, Barcelona
Royal Free Hospital, London
Collaborators (2)
Cytheris SA
INDUSTRY
Merck Sharp & Dohme LLC
INDUSTRY
Pfizer
INDUSTRY
Objectif Recherche Vaccins SIDA
OTHER